TRIM25-mediated KLF5 degradation contributes to enzalutamide resistance through SLC7A11 upregulation and ferroptosis suppression in castration-resistant prostate cancer
Background Enzalutamide improves outcomes in castration-resistant prostate cancer (CRPC), yet nearly all patients develop acquired resistance. Although suppression of ferroptosis has emerged as a mechanism contributing to enzalutamide resistance, the upstream regulators linking androgen receptor blockade to ferroptosis escape remain poorly defined. Krüppel-like factor 5 (KLF5) is a transcription factor implicated in prostate cancer progression, but its role in ferroptosis regulation and therapeutic resistance is unknown. Methods We integrated C4-2 cell RNA sequencing, KLF5 immunoprecipitation–LC-MS/MS, genetic gain- and loss-of-function assays, dual-luciferase reporter and chromatin immunoprecipitation assays, biochemical and promoter validation, ferroptosis phenotyping (including lipid peroxidation, intracellular Fe²⁺, GSH measurement, and mitochondrial morphology), public-dataset analyses, and CRPC xenograft models to define the TRIM25–KLF5–SLC7A11 pathway in enzalutamide resistance. Cycloheximide chase, ubiquitination, and site-directed mutagenesis experiments were used to elucidate the post-translational regulation of KLF5. Results We identified a TRIM25–KLF5–SLC7A11 regulatory axis that suppresses ferroptosis and drives enzalutamide resistance. Enzalutamide-resistant CRPC cells exhibited reduced KLF5 protein but preserved KLF5 mRNA, indicating post-translational regulation. Mechanistically, enzalutamide induced the E3 ubiquitin ligase TRIM25, which physically interacted with KLF5 and promoted its ubiquitination and proteasomal degradation at lysine 369. Loss of nuclear KLF5 relieved transcriptional repression of the cystine/glutamate antiporter SLC7A11, resulting in enhanced cystine uptake, increased glutathione biosynthesis, attenuated lipid peroxidation, and ultimately ferroptosis resistance. KLF5 restoration enhanced ferroptosis-associated responses in ENZ-resistant cells; in erastin-treated ENZ-R xenografts, KLF5 overexpression was associated with increased 4-HNE staining and lower tumor burden. Clinically, TRIM25 was significantly upregulated in advanced and metastatic prostate cancer and correlated with adverse prognosis, whereas KLF5 expression inversely correlated with SLC7A11 levels across multiple patient cohorts. Conclusions These findings reveal a ubiquitin-dependent mechanism linking androgen receptor blockade to ferroptosis escape and establish the TRIM25–KLF5–SLC7A11 signaling axis as a mechanistically grounded therapeutic vulnerability in enzalutamide-resistant CRPC. Modulation of this axis alters ferroptosis susceptibility and enzalutamide responses in CRPC cell models, supporting further preclinical investigation.
Authors
- Zheng Yang (ORCID: https://orcid.org/0000-0002-6169-3061)
- Peng Guo (ORCID: https://orcid.org/0000-0002-4575-8443)
- Renfei Yuan
- Dalin He (ORCID: https://orcid.org/0000-0002-4403-7935)
- Fei Zhang
- Wei Lv
- Yanan Wang
- Jianbin Ma
- Yi Sun
- Fangfang Lu
Institutions
- Shaanxi Provincial People's Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s13402-026-01332-0
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00